[KSCI] Korea Science Citation Index Service

http://dx.doi.org/10.14348/molcells.2016.2350

An Integrative Approach to Precision Cancer Medicine Using Patient-Derived Xenografts

Cho, Sung-Yup (Department of Life Science, Ewha Womans University)
Kang, Wonyoung (Department of Life Science, Ewha Womans University)
Han, Jee Yun (Department of Life Science, Ewha Womans University)
Min, Seoyeon (Department of Life Science, Ewha Womans University)
Kang, Jinjoo (Department of Life Science, Ewha Womans University)
Lee, Ahra (Department of Life Science, Ewha Womans University)
Kwon, Jee Young (Department of Life Science, Ewha Womans University)
Lee, Charles (Department of Life Science, Ewha Womans University)
Park, Hansoo (Department of Life Science, Ewha Womans University)

Abstract

Cancer is a heterogeneous disease caused by diverse genomic alterations in oncogenes and tumor suppressor genes. Despite recent advances in high-throughput sequencing technologies and development of targeted therapies, novel cancer drug development is limited due to the high attrition rate from clinical studies. Patient-derived xenografts (PDX), which are established by the transfer of patient tumors into immunodeficient mice, serve as a platform for co-clinical trials by enabling the integration of clinical data, genomic profiles, and drug responsiveness data to determine precisely targeted therapies. PDX models retain many of the key characteristics of patients' tumors including histology, genomic signature, cellular heterogeneity, and drug responsiveness. These models can also be applied to the development of biomarkers for drug responsiveness and personalized drug selection. This review summarizes our current knowledge of this field, including methodologic aspects, applications in drug development, challenges and limitations, and utilization for precision cancer medicine.

Keywords

cancer drug development; cancer genomics; patient-derived xenografts; precision medicine;

Citations & Related Records

Reference

1	Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004). EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. USA 101, 13306- 13311. DOI
2	Park, H., Cho, S.Y., Kim, H., Na, D., Han, J.Y., Chae, J., Park, C., Park, O.K., Min, S, Kang, J., et al. (2015). Genomic alterations in BCL2L1 and DLC1 contribute to drug sensitivity in gastric cancer. Proc. Natl. Acad. Sci. USA 112, 12492-12497. DOI
3	Quintas-Cardama, A., and Cortes, J. (2009). Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood 113, 1619- 1630. DOI
4	Reyal, F., Guyader, C., Decraene, C., Lucchesi, C., Auger, N., Assayag, F., De Plater, L., Gentien, D., Poupon, M.F., Cottu, P., et al. (2012). Molecular profiling of patient-derived breast cancer xenografts. Breast Cancer Res. 14, R11. DOI
5	Reyes, G., Villanueva, A., Garcia, C., Sancho, F.J., Piulats, J., Lluis, F., and Capella, G. (1996). Orthotopic xenografts of human pancreatic carcinomas acquire genetic aberrations during dissemination in nude mice. Cancer Res. 56, 5713-5719.
6	Rongvaux, A., Willinger, T., Martinek, J., Strowig, T., Gearty, S.V., Teichmann, L.L., Saito, Y., Marches, F., Halene, S., Palucka, A.K., et al. (2014). Development and function of human innate immune cells in a humanized mouse model. Nat. Biotechnol. 32, 364-U230. DOI
7	Rosen, J.M., and Jordan, C.T. (2009). The increasing complexity of the cancer stem cell paradigm. Science 324, 1670-1673. DOI
8	Rosfjord, E., Lucas, J., Li, G., and Gerber, H.P. (2014). Advances in patient-derived tumor xenografts: From target identification to predicting clinical response rates in oncology. Biochem. Pharmacol. 91, 135-143. DOI
9	Von Hoff, D.D., Ramanathan, R.K., Borad, M.J., Laheru, D.A., Smith, L.S., Wood, T.E., Korn, R.L., Desai, N., Trieu, V., Iglesias, J.L., et al. (2011). Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J. Clin. Oncol. 29, 4548-4554. DOI
10	Von Hoff, D.D., Ervin, T., Arena, F.P., Chiorean, E.G., Infante, J., Moore, M., Seay, T., Tjulandin, S.A., Ma, W.W., Saleh, M.N., et al. (2013). Increased survival in pancreatic cancer with nabpaclitaxel plus gemcitabine. N. Engl. J. Med. 369, 1691-1703. DOI
11	Weinstein, J.N., Collisson, E.A., Mills, G.B., Shaw, K.R.M., Ozenberger, B.A., Ellrott, K., Shmulevich, I., Sander, C., and Stuart, J.M. (2013). The cancer genome atlas pan-cancer analysis project. Nat. Genet. 45, 1113-1120. DOI
12	Wetterauer, C., Vlajnic, T., Schuler, J., Gsponer, J.R., Thalmann, G.N., Cecchini, M., Schneider, J., Zellweger, T., Pueschel, H., Bachmann, A., et al. (2015). Early development of human lymphomas in a prostate cancer xenograft program using triple knock-out immunocompromised mice. Prostate 75, 585-592. DOI
13	Whittle, J.R., Lewis, M.T., Lindeman, G.J., and Visvader, J.E. (2015). Patient-derived xenograft models of breast cancer and their predictive power. Breast Cancer Res. 17, 17. DOI
14	Williams, S.A., Anderson, W.C., Santaguida, M.T., and Dylla, S.J. (2013). Patient-derived xenografts, the cancer stem cell paradigm, and cancer pathobiology in the 21st century. Lab. Invest. 93, 970-982. DOI
15	Zhang, X.M., Claerhout, S., Prat, A., Dobrolecki, L.E., Petrovic, I., Lai, Q., Landis, M.D., Wiechmann, L., Schiff, R., Giuliano, M., et al. (2013). A Renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. Cancer Res. 73, 4885-4897. DOI
16	Bertolini, G., Roz, L., Perego, P., Tortoreto, M., Fontanella, E., Gatti, L., Pratesi, G., Fabbri, A., Andriani, F., Tinelli, S., et al. (2009). Highly tumorigenic lung cancer CD133(+) cells display stem-like features and are spared by cisplatin treatment. Proc. Natl. Acad. Sci. USA 106, 16281-16286. DOI
17	Agliano, A., Martin-Padura, I., Mancuso, P., Marighetti, P., Rabascio, C., Pruneri, G., Shultz, L.D., and Bertolini, F. (2008). Human acute leukemia cells injected in NOD/LtSz-scid/IL- $2R\gamma$ null mice generate a faster and more efficient disease compared to other NOD/scid-related strains. Int. J. Cancer 123, 2222-2227. DOI
18	Aparicio, S., Hidalgo, M., and Kung, A.L. (2015). Examining the utility of patient-derived xenograft mouse models. Nat. Rev. Cancer 15, 311-316. DOI
19	Aytes, A., Mollevi, D.G., Martinez-Iniesta, M., Nadal, M., Vidal, A., Morales, A., Salazar, R., Capella, G., and Villanueva, A. (2012). Stromal interaction molecule 2 (STIM2) is frequently overexpressed in colorectal tumors and confers a tumor cell growth suppressor phenotype. Mol. Carcinog. 51, 746-753. DOI
20	Bell, D., Berchuck, A., Birrer, M., Chien, J., Cramer, D.W., Dao, F., Dhir, R., DiSaia, P., Gabra, H., Glenn, P., et al. (2011). Integrated genomic analyses of ovarian carcinoma. Nature 474, 609-615. DOI
21	Bertotti, A., Migliardi, G., Galimi, F., Sassi, F., Torti, D., Isella, C., Cora, D., Di Nicolantonio, F., Buscarino, M., Petti, C., et al. (2011). A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov. 1, 508-523. DOI
22	Chen, K., Ahmed, S., Adeyi, O., Dick, J.E., and Ghanekar, A. (2012). Human solid tumor xenografts in immunodeficient mice are vulnerable to lymphomagenesis associated with Epstein-Barr virus. PLoS One 7, e39294. DOI
23	Choi, S.Y.C., Lin, D., Gout, P.W., Collins, C.C., Xu, Y., and Wang, Y.Z. (2014). Lessons from patient-derived xenografts for better in vitro modeling of human cancer. Adv. Drug Deliver. Rev. 79-80, 222-237. DOI
24	Das Thakur, M., Salangsang, F., Landman, A.S., Sellers, W.R., Pryer, N.K., Levesque, M.P., Dummer, R., McMahon, M., and Stuart, D.D. (2013). Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature 494, 251-255. DOI
25	DiMasi, J.A., Reichert, J.M., Feldman, L., and Malins, A. (2013). Clinical approval success rates for investigational cancer drugs. Clin. Pharmacol. Ther. 94, 329-335. DOI
26	de Groot, J.F., Fuller, G., Kumar, A.J., Piao, Y., Eterovic, K., Ji, Y.J., and Conrad, C.A. (2010). Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro. Oncol. 12, 233-242. DOI
27	Delitto, D., Pham, K., Vlada, A.C., Sarosi, G.A., Thomas, R.M., Behrns, K.E., Liu, C., Hughes, S.J., Wallet, S.M., and Trevino, J.G. (2015). Patient-derived xenograft models for pancreatic adenocarcinoma demonstrate retention of tumor morphology through incorporation of murine stromal elements. Am. J. Pathol. 185, 1297-1303. DOI
28	DeRose, Y.S., Wang, G.Y., Lin, Y.C., Bernard, P.S., Buys, S.S., Ebbert, M.T.W., Factor, R., Matsen, C., Milash, B.A., Nelson, E., et al. (2011). Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat. Med. 17, 1514-1520 DOI
29	Ding, L., Ellis, M.J., Li, S.Q., Larson, D.E., Chen, K., Wallis, J., Harris, C.C., McLellan, M.D., Fulton, R.S., Fulton, L.L., et al. (2010). Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 464, 999-1005. DOI
30	Dong, X., Guan, J., English, J.C., Flint, J., Yee, J., Evans, K., Murray, N., Macaulay, C., Ng, R.T., Gout, P.W., et al. (2010). Patientderived first generation xenografts of non-small cell lung cancers: promising tools for predicting drug responses for personalized chemotherapy. Clin. Cancer Res. 16, 1442-1451. DOI
31	Dowst, H., Pew, B., Watkins, C., McOwiti, A., Barney, J., Qu, S., Becnel, L. B. (2015). Acquire: an open-source comprehensive cancer biobanking system. Bioinformatics 31, 1655-1662. DOI
32	Gao, D., and Chen, Y. (2015). Organoid development in cancer genome discovery. Curr. Opin. Genet. Dev. 30, 42-48. DOI
33	Eirew, P., Steif, A., Khattra, J., Ha, G., Yap, D., Farahani, H., Gelmon, K., Chia, S., Mar, C., Wan, A., et al. (2015). Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution. Nature 518, 422-426. DOI
34	Fernandez de Sanmamamed, M., Lopez Rodriguez, I., Schalper, K.A., Onate, C., Azpilikueta, A., Rodriguez-Ruiz, M.E., Morales- Kastresana, A., Labiano, S., Perez-Gracia, J.L., Martin-Algarra, S., et al. (2015). Nivolumab and urelumab enhance antitumor activity of human T lymphocytes engrafted in Rag2-/-IL2R $\gamma$ null immunodeficient mice. Cancer Res. 75, 3466-3478. DOI
35	Fichtner, I., Rolff, J., Soong, R., Hoffmann, J., Hammer, S., Sommer, A., Becker, M., and Merk, J. (2008). Establishment of patientderived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers. Clin. Cancer Res. 14, 6456-6468. DOI
36	Gao, H., Korn, J.M., Ferretti, S., Monahan, J.E., Wang, Y., Singh, M., Zhang, C., Schnell, C., Yang, G., Zhang, Y., et al. (2015). Highthroughput screening using patient-derived tumor xenografts to predict clinical trial drug response. Nat. Med. 21, 1318-1325. DOI
37	Garraway, L.A., Verweij, J., and Ballman, K.V. (2013). Precision oncology: an overview. J. Clin. Oncol. 31, 1803-1805. DOI
38	Garrido-Laguna, I., Uson, M., Rajeshkumar, N.V., Tan, A.C., de Oliveira, E., Karikari, C., Villaroel, M.C., Salomon, A., Taylor, G., Sharma, R., et al. (2011). Tumor engraftment in nude mice and enrichment in stroma-related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer. Clin. Cancer Res. 17, 5793-5800. DOI
39	Hidalgo, M., Bruckheimer, E., Rajeshkumar, N.V., Garrido-Laguna, I., De Oliveira, E., Rubio-Viqueira, B., Strawn, S., Wick, M.J., Martell, J., and Sidransky, D. (2011). A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. Mol. Cancer Ther. 10, 1311-1316. DOI
40	Girotti, M.R., Lopes, F., Preece, N., Niculescu-Duvaz, D., Zambon, A., Davies, L., Whittaker, S., Saturno, G., Viros, A., Pedersen, M., et al. (2015). Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma. Cancer Cell 27, 85-96. DOI
41	Hidalgo, M., Amant, F., Biankin, A.V., Budinska, E., Byrne, A.T., Caldas, C., Clarke, R.B., de Jong, S., Jonkers, J., Maelandsmo, G.M., et al. (2014). Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov. 4, 998-1013. DOI
42	Hoffman, R.M. (2015). Patient-derived orthotopic xenografts: better mimic of metastasis than subcutaneous xenografts. Nat. Rev. Cancer 15, 451-452. DOI
43	John, T., Yanagawa, N., Kohler, D., Craddock, K.J., Bandarchi- Chamkhaleh, B., Pintilie, M., Sykes, J., To, C., Li, M., Panchal, D., et al. (2012). Characterization of lymphomas developing in immunodeficient mice implanted with primary human non-small cell lung cancer. J. Thorac. Oncol. 7, 1101-1108. DOI
44	Johnson, J.I., Decker, S., Zaharevitz, D., Rubinstein, L.V., Venditti, J., Schepartz, S., Kalyandrug, S., Christian, M., Arbuck, S., Hollingshead, M., et al. (2001). Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br. J. Cancer 84, 1424-1431. DOI
45	Keysar, S.B., Astling, D.P., Anderson, R.T., Vogler, B.W., Bowles, D.W., Morton, J.J., Paylor, J.J., Glogowska, M.J., Le, P.N., Eagles- Soukup, J.R., et al. (2013). A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins. Mol. Oncol. 7, 776- 790. DOI
46	Joo, K.M., Kim, J., Jin, J., Kim, M., Seol, H.J., Muradov, J., Yang, H., Choi, Y.L., Park, W.Y., Kong, D.S., et al. (2013). Patient-specific orthotopic glioblastoma xenograft models recapitulate the histopathology and biology of human glioblastomas in situ. Cell Rep. 3, 260-273. DOI
47	Julien, S., Merino-Trigo, A., Lacroix, L., Pocard, M., Goere, D., Mariani, P., Landron, S., Bigot, L., Nemati, F., Dartigues, P., et al. (2012). Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer. Clin. Cancer Res. 18, 5314-5328. DOI
48	Kimple, R.J., Harari, P.M., Torres, A.D., Yang, R.Z., Soriano, B.J., Yu, M., Armstrong, E.A., Blitzer, G.C., Smith, M.A., Lorenz, L.D., et al. (2013). Development and characterization of HPV-positive and HPV-negative head and neck squamous cell carcinoma tumorgrafts. Clin. Cancer Res. 19, 855-864. DOI
49	Koboldt, D.C., Fulton, R.S., McLellan, M.D., Schmidt, H., Kalicki- Veizer, J., McMichael, J.F., Fulton, L.L., Dooling, D.J., Ding, L., Mardis, E.R., et al. (2012). Comprehensive molecular portraits of human breast tumours. Nature 490, 61-70. DOI
50	Kopetz, S., Lemos, R., and Powis, G. (2012). The promise of patient- derived xenografts: the best laid plans of mice and men. Clin. Cancer Res. 18, 5160-5162. DOI
51	Kung, A.L. (2007). Practices and pitfalls of mouse cancer models in drug discovery. Adv. Cancer Res. 96, 191-212.
52	Lin, D., Wyatt, A. W., Xue, H., Wang, Y., Dong, X., Haegert, A., Wu, R., Brahmbhatt, S., Mo, F., Jong, L., et al. (2014). High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development. Cancer Res. 74, 1271-1283. DOI
53	Lai, A., Tran, A., Nghiemphu, P.L., Pope, W.B., Solis, O.E., Selch, M., Filka, E., Yong, W.H., Mischel, P.S., Liau, L.M., et al. (2011). Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J. Clin. Oncol. 29, 142-148. DOI
54	Landis, M.D., Lehmann, B.D., Pietenpol, J.A., and Chang, J.C. (2013). Patient-derived breast tumor xenografts facilitating personalized cancer therapy. Breast Cancer Res. 15, 201. DOI
55	Li, S.Q., Shen, D., Shao, J.Y., Crowder, R., Liu, W.B., Prat, A., He, X.P., Liu, S.Y., Hoog, J., Lu, C., et al. (2013). Endocrine-therapyresistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep. 4, 1116-1130. DOI
56	Macconaill, L.E., and Garraway, L.A. (2010). Clinical implications of the cancer genome. J. Clin. Oncol. 28, 5219-5228. DOI
57	Marangoni, E., Vincent-Salomon, A., Auger, N., Degeorges, A., Assayag, F., de Cremoux, P., de Plater, L., Guyader, C., De Pinieux, G., Judde, J.G., et al. (2007). A new model of patient tumorderived breast cancer xenografts for preclinical assays. Clin. Cancer Res. 13, 3989-3998. DOI
58	Masso-Valles, D., Jauset, T., Serrano, E., Sodir, N.M., Pedersen, K., Affara, N.I., Whitfield, J.R., Beaulieu, M.E., Evan, G.I., Elias, L., et al. (2015). Ibrutinib exerts potent antifibrotic and antitumor activities in mouse models of pancreatic adenocarcinoma. Cancer Res. 75, 1675-1681. DOI
59	Morton, C.L., and Houghton, P.J. (2007). Establishment of human tumor xenografts in immunodeficient mice. Nat. Protoc. 2, 247- 250. DOI
60	Mattie, M., Christensen, A., Chang, M.S., Yeh, W., Said, S., Shostak, Y., Capo, L., Verlinsky, A., An, Z.L., Joseph, I., et al. (2013). Molecular characterization of patient-derived human pancreatic tumor xenograft models for preclinical and translational development of cancer therapeutics. Neoplasia 15, 1124-1136.
61	Morton, J.J., Bird, G., Keysar, S.B., Astling, D.P., Lyons, T.R., Anderson, R.T., Glogowska, M.J., Estes, P., Eagles, J.R., Le, P.N., et al. (2015). XactMice: humanizing mouse bone marrow enables microenvironment reconstitution in a patient-derived xenograft model of head and neck cancer. Oncogene (Epub ahead of print).
62	Muzny, D.M., Bainbridge, M.N., Chang, K., Dinh, H.H., Drummond, J.A., Fowler, G., Kovar, C.L., Lewis, L.R., Morgan, M.B., Newsham, I.F., et al. (2012). Comprehensive molecular characterization of human colon and rectal cancer. Nature 487, 330-337. DOI
63	Nardella, C., Lunardi, A., Patnaik, A., Cantley, L.C., and Pandolfi, P.P. (2011). The APL paradigm and the "co-clinical trial" project. Cancer Discov. 1, 108-116. DOI
64	Nemati, F., Sastre-Garau, X., Laurent, C., Couturier, J., Mariani, P., Desjardins, L., Piperno-Neumann, S., Lantz, O., Asselain, B., Plancher, C., et al. (2010). Establishment and characterization of a panel of human uveal melanoma xenografts derived from primary and/or metastatic tumors. Clin. Cancer Res. 16, 2352- 2362. DOI
65	Ostman, A. (2012). The tumor microenvironment controls drug sensitivity. Nat. Med. 18, 1332-1334. DOI
66	Siolas, D., and Hannon, G.J. (2013). Patient-derived tumor xenografts: transforming clinical samples into mouse models. Cancer Res. 73, 5315-5319. DOI
67	Schatton, T., Murphy, G.F., Frank, N.Y., Yamaura, K., Waaga- Gasser, A.M., Gasser, M., Zhan, Q., Jordan, S., Duncan, L.M., Weishaupt, C., et al. (2008). Identification of cells initiating human melanomas. Nature 451, 345-349. DOI
68	Scott, C.L., Becker, M.A., Haluska, P., and Samimi, G. (2013). Patient- derived xenograft models to improve targeted therapy in epithelial ovarian cancer treatment. Front. Oncol. 3, 295.
69	Shaw, A.T., Yeap, B.Y., Solomon, B.J., Riely, G.J., Gainor, J., Engelman, J.A., Shapiro, G.I., Costa, D.B., Ou, S.H.I., Butaney, M., et al. (2011). Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol. 12, 1004-1012. DOI
70	Slamon, D., Eiermann, W., Robert, N., Pienkowski, T., Martin, M., Press, M., Mackey, J., Glaspy, J., Chan, A., Pawlicki, M., et al. (2011). Adjuvant trastuzumab in HER2-positive breast cancer. N. Engl. J. Med. 365, 1273-1283. DOI
71	Tentler, J.J., Tan, A.C., Weekes, C.D., Jimeno, A., Leong, S., Pitts, T.M., Arcaroli, J.J., Messersmith, W.A., and Eckhardt, S.G. (2012). Patient-derived tumour xenografts as models for oncology drug development. Nat. Rev. Clin. Oncol. 9, 338-350. DOI
72	Verhaak, R.G.W., Hoadley, K.A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M.D., Miller, C.R., Ding, L., Golub, T., Mesirov, J.P., et al. (2010). Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17, 98-110. DOI
73	Zhao, X.M., Liu, Z.G., Yu, L.T., Zhang, Y.J., Baxter, P., Voicu, H., Gurusiddappa, S., Luan, J., Su, J.M., Leung, H.C.E., et al. (2012). Global gene expression profiling confirms the molecular fidelity of primary tumor-based orthotopic xenograft mouse models of medulloblastoma. Neuro. Oncol. 14, 574-583. DOI
74	Zhang, L.H., Liu, Y.Q., Wang, X.H., Tang, Z.Y., Li, S.X., Hu, Y., Zong, X.L., Wu, X.J., Bu, Z.D., Wu, A.W., et al. (2015). The extent of in flammatory infiltration in primary cancer tissues is associated with lymphomagenesis in immunodeficient mice. Sci. Rep. 5, 9447. DOI

Reference

7	Joana Torres. (2016) Gut Preclinical disease and preventive strategies in IBD: perspectives, challenges and opportunities / 65 (7) , 1061
	Ryoji Ito. (2018) Journal of Cellular Physiology Humanized mouse models: Application to human diseases /
	Diana Behrens. (2017) Pharmacology & Therapeutics Pancreatic cancer models for translational research / 173 , 146
5	Takahiro Inoue. (2017) Nature Reviews Urology Patient-derived xenografts as in vivo models for research in urological malignancies / 14 (5) , 267
	Emilee Senkevitch. (2017) Cytokine The promise of Janus kinase inhibitors in the treatment of hematological malignancies / 98 , 33
1	Chen Chen. (2017) Scientific Reports A multiplex preclinical model for adenoid cystic carcinoma of the salivary gland identifies regorafenib as a potential therapeutic drug / 7 (1)
	Seung Ho Shin. (2017) EBioMedicine A Small Molecule Inhibitor of the β-Catenin-TCF4 Interaction Suppresses Colorectal Cancer Growth In Vitro and In Vivo /
11	Takahito Sugase. (2017) International Journal of Cancer Suppressor of cytokine signaling-1 gene therapy induces potent antitumor effect in patient-derived esophageal squamous cell carcinoma xenograft mice / 140 (11) , 2608
	William K. Decker. (2017) Frontiers in Immunology Cancer Immunotherapy: Historical Perspective of a Clinical Revolution and Emerging Preclinical Animal Models / 8
1	(2018) Scientific Reports Patient-derived conditionally reprogrammed cells maintain intra-tumor genetic heterogeneity / 8 (1)
1	(2018) Journal of Biomedical Science Tumor xenograft animal models for esophageal squamous cell carcinoma / 25 (1)
2	(2019) Expert Opinion on Drug Discovery Animal models for modeling pancreatic cancer and novel drug discovery / 14 (2) , 127
None	(2016) Journal of visualized experiments : JoVE Transplantation of Zebrafish Pediatric Brain Tumors into Immune-competent Hosts for Long-term Study of Tumor Cell Behavior and Drug Response / 123 (None) , 55712
6	(2018) World Journal of Stem Cells Murine models based on acute myeloid leukemia-initiating stem cells xenografting / 10 (6) , 57
37	(2018) RSC Advances simulation of pancreatic ductal adenocarcinoma / 8 (37) , 20928
1	(2018) Cancer Research and Treatment The Generation and Application of Patient-Derived Xenograft Model for Cancer Research / 50 (1) , 1
1664-302X	(2018) Frontiers in Microbiology Bacterial Therapy of Cancer: Promises, Limitations, and Insights for Future Directions / 9 (1664-302X)
17	(2018) Blood Alterations in the Rho pathway contribute to Epstein-Barr virus–induced lymphomagenesis in immunosuppressed environments / 131 (17) , 1931
9	(2016) Molecular cancer research Targeting RRM2 and Mutant BRAF Is a Novel Combinatorial Strategy for Melanoma / 14 (9) , 767
19	(2016) Cancer research : the official organ of the American Association for Cancer Research, Inc The Challenge of Developing Autophagy Inhibition as a Therapeutic Strategy / 76 (19) , 5610
24	(2017) Cancer research : the official organ of the American Association for Cancer Research, Inc H3B-6527 Is a Potent and Selective Inhibitor of FGFR4 in FGF19-Driven Hepatocellular Carcinoma / 77 (24) , 6999
2	(2016) Current molecular biology reports Modelomics to Investigate Cancer Bone Metastasis / 4 (2) , 88
17	(2016) Theranostics Mesenchymal glioblastoma constitutes a major ceRNA signature in the TGF-β pathway / 8 (17) , 4733
None	(2018) Biomedicine & pharmacotherapy Alpha, 2’-dihydroxy-4,4’-dimethoxydihydrochalcone inhibits cell proliferation, invasion, and migration in gastric cancer in part <I>via</I> autophagy / 98 (None) , 709
3	(2018) Future science OA Use of patient-derived xenograft mouse models in cancer research and treatment / 4 (3) , FSO271
8	(2016) BMJ open Protocol for the avatar acceptability study: a multiperspective cross-sectional study evaluating the acceptability of using patient-derived xenografts to guide personalised cancer care in Australia an / 8 (8) , e024064
2	(2016) Current hematologic malignancy reports Development and Significance of Mouse Models in Lymphoma Research / 14 (2) , 119
22	(2016) Chinese medical journal : CMJ Generation and application of patient-derived xenograft models in pancreatic cancer research / 132 (22) , 2729
1	(2016) The FASEB journal : official publication of the Federation of American Societies for Experimental Biology Oncological and genetic factors impacting PDX model construction with NSG mice in pancreatic cancer / 33 (1) , 873
2	(2016) Medicinskaâ immunologiâ SELECTED ASPECTS OF ALLO- AND XENOGRAFT MODEL APPLICATIONS FOR DEVELOPING NOVEL ANTI-CANCER VACCINES AND ONCOLYTIC VIRUSES / 21 (2) , 221
5	(2016) Cells Systematic Review of Patient-Derived Xenograft Models for Preclinical Studies of Anti-Cancer Drugs in Solid Tumors / 8 (5) , 418
9	(2016) International journal of cancer: Journal international du cancer CTCs‐derived xenograft development in a triple negative breast cancer case / 144 (9) , 2254
9	(2019) Clinical Cancer research : an official journal of the American Association for Cancer Research Unstable Genome and Transcriptome Dynamics during Tumor Metastasis Contribute to Therapeutic Heterogeneity in Colorectal Cancers / 25 (9) , 2821
8	(2016) Cells Application of Highly Immunocompromised Mice for the Establishment of Patient-Derived Xenograft (PDX) Models / 8 (8) , 889
3	(2016) Animal models and experimental medicine The promises and challenges of patient‐derived tumor organoids in drug development and precision oncology / 2 (3) , 150
11	(2016) Journal of tissue engineering and regenerative medicine Review on biofabrication and applications of heterogeneous tumor models / 13 (11) , 2101
1	(2019) BMC medical genomics Genomic data analysis workflows for tumors from patient-derived xenografts (PDXs): challenges and guidelines / 12 (1) , 92
1	(2019) Genome biology Impact of mouse contamination in genomic profiling of patient-derived models and best practice for robust analysis / 20 (1) , 231
12	(2016) PLoS ONE Establishment of chemosensitivity tests in triple-negative and BRCA-mutated breast cancer patient-derived xenograft models / 14 (12) , e0225082
None	(2016) OncoTargets and therapy HSP90 Inhibitor Ganetespib (STA-9090) Inhibits Tumor Growth in c-Myc-Dependent Esophageal Squamous Cell Carcinoma / 13 (None) , 2997
5	(2020) Zoological research : ZR Breast cancer animal models and applications / 41 (5) , 477
7	(2016) Journal of Cancer Targeting antisense mitochondrial noncoding RNAs induces bladder cancer cell death and inhibition of tumor growth through reduction of survival and invasion factors / 11 (7) , 1780
1	(2020) PLoS ONE High expression of olfactomedin-4 is correlated with chemoresistance and poor prognosis in pancreatic cancer / 15 (1) , e0226707
None	(2016) Laboratory animal research Patient-derived xenografts as compatible models for precision oncology / 36 (None) , 14
6	(2016) The Journal of nuclear medicine : JNM Preclinical PERCIST and 25% of SUV<SUB>max</SUB> Threshold: Precision Imaging of Response to Therapy in Co-clinical <SUP>18</SUP>F-FDG PET Imaging of Triple-Negative Breast Cancer Patient–Deriv / 61 (6) , 842
11	(2016) Cancer research : the official organ of the American Association for Cancer Research, Inc Systematic Establishment of Robustness and Standards in Patient-Derived Xenograft Experiments and Analysis / 80 (11) , 2286
1	(2016) Oncology reports High expression levels of polymeric immunoglobulin receptor are correlated with chemoresistance and poor prognosis in pancreatic cancer / 44 (1) , 252
3	(2016) Tomography : an international journal for imaging research Co-Clinical Imaging Resource Program (CIRP): Bridging the Translational Divide to Advance Precision Medicine / 6 (3) , 273
3	(2020) Journal of personalized medicine Patient-Derived Tumor Xenograft Models: Toward the Establishment of Precision Cancer Medicine / 10 (3) , 64
1	(2020) Journal of translational medicine Development and optimization of orthotopic liver metastasis xenograft mouse models in uveal melanoma / 18 (1) , 208
1	(2016) Journal of Cancer The Essential Factors of Establishing Patient-derived Tumor Model / 12 (1) , 28
1	(2016) International journal of oncology High levels of human epididymis protein 4 mRNA and protein expression are associated with chemoresistance and a poor prognosis in pancreatic cancer / 58 (1) , 57
2	(2021) Clinical and translational medicine Understanding cell‐cell communication and signaling in the colorectal cancer microenvironment / 11 (2) , None
8	(2021) Animals Establishment and Characterization of Feline Mammary Tumor Patient-Derived Xenograft Model / 11 (8) , 2380
5	(2016) Nutrients Comparative Gene Signature of (−)-Oleocanthal Formulation Treatments in Heterogeneous Triple Negative Breast Tumor Models: Oncological Therapeutic Target Insights / 13 (5) , 1706
12	(2016) Cancers An Overview on Diffuse Large B-Cell Lymphoma Models: Towards a Functional Genomics Approach / 13 (12) , 2893
13	(2021) JCI insight Natural killer cells and cytotoxic T lymphocytes are required to clear solid tumor in a patient-derived xenograft / 6 (13) , e140116
17	(2021) International journal of molecular sciences Patient-Derived Xenograft Models in Cervical Cancer: A Systematic Review / 22 (17) , 9369
10	(2016) Biomedicines Predicting Cancer Drug Response In Vivo by Learning an Optimal Feature Selection of Tumour Molecular Profiles / 9 (10) , 1319
24	(2016) Cancers Patient-Derived Xenografts of High-Grade Serous Ovarian Cancer Subtype as a Powerful Tool in Pre-Clinical Research / 13 (24) , 6288